GlassScriptPhysician profile
Rolondo Brown
NPI 1073933800
$594.74
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.34 · 2022: $40.23 · 2023: $137 · 2024: $205 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.36 | 2022-2024 | |
| Smith+Nephew, INC. | $74.48 | 2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.04 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Alexion Pharmaceuticals, INC. | $50.38 | 2024 | Ultomiris, Soliris |
| Amgen INC. | $46.18 | 2024-2025 | Repatha |
| Gilead Sciences, INC. | $41.05 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.66 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.96 | 2025 | Lifevest |
| Melinta Therapeutics, LLC | $25.84 | 2024 | Orbactiv |
| Abbott Laboratories | $21.41 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $21.08 | 2025 | Eliquis |
| Solventum Corporation | $20.65 | 2024 | V.A.C. Veraflo Cleanse Choice |
| Janssen Pharmaceuticals, INC | $15.48 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolondo Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.